Fig. 6: UBE2F protects lung cancer cells from platinum chemotherapy in vivo. | Cell Death & Disease

Fig. 6: UBE2F protects lung cancer cells from platinum chemotherapy in vivo.

From: Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity

Fig. 6

A–D UBE2F protects tumors from platinum-induced growth inhibition. Nude mice with xenografts were treated as in Fig. 5A. Tumor xenografts were measured for size (A) and weight (B). The expression levels of UBE2F and NOXA were determined by western blot (C, D). Shown are average values with standard deviation (s.d.). *P < 0.05 and ***P < 0.001 for the indicated comparison; n.s. not significant. E A working model illustrating the role of UBE2F in platinum sensitivity. Shown is a working model depicting that upregulation of neddylation E2 UBE2F is an important way for cancer cells to escape platinum-induced cell apoptosis, which is supported by the deletion of UBE2F promotes platinum-induced apoptosis. Platinum impaired the interaction of the UBE2F–RBX1 complex and subsequently inhibited its degradation, resulting in the degradation of NOXA and consequently inducing apoptotic resistance to platinum chemotherapy.

Back to article page